Johnson & Johnson sees FY24 adjusted EPS $10.55-$10.75, consensus $10.78

Sees FY24 operational sales up 5%-6%, consensus $88.47B. The company’s 2024 guidance range reflects an approximate 15c dilutive impact to adjusted operational EPS associated with the previously announced acquisition of Laminar, Inc. Johnson & Johnson is hosting a meeting with the investment community at the New York Stock Exchange to present the company’s overarching strategy, its innovative medicine and MedTech pipelines and long-term financial outlook. “Science and technology will advance human health more in the next decade than it has in the last century, leading to more effective and personalized treatment, earlier intervention, and smarter, less invasive healthcare,” said Joaquin Duato, chairman and CEO. “We are excited to share today how the breadth of our scientific capabilities, diverse portfolio and robust pipelines uniquely position Johnson & Johnson to be a leader in this next wave of innovation while delivering strong financial performance.”